All Compounds

Antimicrobial Resistance

Molecule Name

Category

Phase (F & D, Pre- Clinical,1, 2, 3, Submitted, Approved)

VRP-001

Antibiotic Oral Therapy

VRP 001 is an oral antibiotic adjuvant entity (AAE) based on stealth targeted nanoparticle (STN) technology. The product is designed to meet unmet need of shifting a MDR patients from IV to oral therapy in infections caused by ESBL (Extended Spectrum Beta-lactamases) and MBL (Metallo-beta-lactamases) producing gram-negative pathogens (such as E.coli, A.baumannii, P.aeruginosa, and K.pneumoniae).

Proposed Indication : ESBL and MBL producing gram negative organisms

VRP-033

Anti Biotic Oral Therapy

VRP 033 is an oral antibiotic adjuvant entity (AAE) based on stealth targeted nanoparticle (STN) and chemical vector mediated compatibility (CVMC) technology for multidrug resistance gram-positive pathogens. This product addresses unmet need of IV-oral shift in MDR gram positive pathogens such as MRSA, VRSA and hGISA

Target : Gram positive pathogens including MRSA

VRE-001

Novel Aminoglycoside

VRE 001 is a novel potent water soluble aminoglycoside antibiotic having broad spectrum of activity against gram-negative pathogens including P. aeruginosa. Target : Target gram negative pathogens including P.aeruginosa, E.coli

VRE-2020

Anti Microbial Peptide

This is a novel NDDS based Anti microbial peptide (AMP) using our platform technology of STN. This can target bacteria based on their cellular transport systems and can also target latent bacteria inside the body by targeting receptor mediated endocytosis. The product is designed for XDR pathogens, both gram positive and gram negative

Target : XDR Gram negative & positive organisms

Oncology

Molecule Name

Category

Phase (F & D, Pre- Clinical,1, 2, 3, Submitted, Approved)

VRP-1620

Cancer Detection

VRP 1620 is a novel linear analogue endothelin B receptor agonist which dilates the blood vessels surrounding tumor and thereby provides selective transient vasodilaltio which when used in adjunct with sonomamography increases specificity and PPV without affecting sensitivity. This would be beneficial for theranostics delivery simultaneously to tumor, thereby enhancing the chances of survival in cancer patients and will help eliminate false positive and false negatives.

Target : Solid Tumors

VRP-007

Anti Cancer Target Delivery

VRP 007 is a novel target-based drug delivery for cancer treatment derived from a platform technology with a novel concept of triple conjugate i.e., Drug-Protein- Polymer-Conjugate (DPPC. This technology helps in targeting active drug moieties to affected site/organs in chronic disease therapies associated with cancer and receptor diseases. This technology has the potential to conjugate a wide range of drugs (physiochemically different) with better selectivity to a defined population of affected organ and reducing the drug related side effects and toxicities which are associated in conventional therapies

Target : Cell signaling proteins/receptor present in tumor cell

Hepatic Disorders

Molecule Name

Category

Phase (F & D, Pre- Clinical,1, 2, 3, Submitted, Approved)

VRP-025

Hepatoprotective

This is a useful amino acid which provides potent antagonism to Cyanide poisoning and reverse liver injury, alcoholic liver disease through multiple targets and mechanisms

Target : Anti oxidant

VRP-027

Hepatoprotective

This is a useful amino acid which provides potent antagonism to Cyanide poisoning and reverse liver injury, alcoholic liver disease (by providing antioxidant effect) through multiple targets and mechanisms. The injectable route is useful for immediate onset of action.

Target : Anti oxidant

Hemostatic

Molecule Name

Category

Phase (F & D, Pre- Clinical,1, 2, 3, Submitted, Approved)

VRP-030 & VRP-031 Combo Kit

Wound Sealant

These are a biodegradable and biocompatible natural polymer based Hemostatic products with advanced clotting technology which can stop bleeding in less than a minute. This is easily usable by a layman ("fire and forget missile" technology, just press for a minute on the bleeding area and remove with water when reach the hospital) and stops the severe bleeding within minutes which is crucial for saving life in hemorrhagic situation. It prolongs the "golden period" for hospitalization from less than 30 minutes to 4-6 h and thereby increases the chances of survival after traumatic injury.

Target : Inonic interaction between RBC and positively charged quaternary ammonium ion of chitosan

VRP-029

Wound Sealant

It is an antibiotic supplemented hemostatic biodegradable and biocompatible polymeric hydrogel with advanced hemostatic effect for large / dirty traumatic wounds & acute burns, Adjuvant in chronic non-healing wounds. Acts against resistant Gram negative microbes as found in dirty wounds. Target : Resistant Gram Negative Microorganism

VRP-028

Wound Sealant

RD015 is a natural fibers having cell adhesion promoting tri-peptide (RGD) sequences useful for cell adhesion and RD014 is a cellulosic biomaterial with high degree of water absorption capacity. These are used in wound dressings as wound filling materials and they acts as molecular sieves and provides a network structure for prompt wound filling, May be used on all types of wounds, such as cuts, abrasions, and scrapes.

Target : Cell adhesion and molecular sieve

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to VRL India, its subsidiaries or affiliates. No use of any VRL India trademark, trade name, or trade dress in this site may be made without the prior written authorization of VRL India, except to identify the product or services of the company.

Back to Top